Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

OBJECTIVES: This study aimed to conduct a thorough analysis of fluid retention-associated adverse events (AEs) associated with BCR::ABL inhibitors. DESIGN: A retrospective pharmacovigilance study. SETTING: Food and Drug Administration Adverse Event Reporting System (FAERS) database for BCR::ABL inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Cai, Juanjuan, Ye, Qingqing, Jiang, Qiaoying, Lin, Huan, Wu, Lun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401248/
https://www.ncbi.nlm.nih.gov/pubmed/37536976
http://dx.doi.org/10.1136/bmjopen-2022-071456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401248/
https://www.ncbi.nlm.nih.gov/pubmed/37536976
http://dx.doi.org/10.1136/bmjopen-2022-071456

Ejemplares similares